We exist to solve for a new era of scale and complexity in science—where Big Biology meets Big Tech, and where old models can’t keep up. We help life sciences organizations move from early development to enterprise value—uniting science, strategy, and storytelling with the speed and precision of AI.
Products Launched
Therapeutic Areas Covered
Percentage of Consultants with Advanced Degrees
Guiding principles for how we think, decide, and create—anchored in science, driven by belief.
Science
Strategy
Storytelling
Artificial Intelligence
Born in AI. Built for what’s next.
We are a new consulting model for life sciences, built for the reality the industry faces today.
Vision
Realize the full promise of the Biology Century— ensuring that no potential for human advancement is left unexplored.
Mission
Empower the pioneers of the Biology Century—ensuring the most important science isn't just discovered, but delivered for humanity.
Purpose
We exist to solve for a new era of scale and complexity in science—where Big Biology meets Big Tech, and where old models can’t keep up.
Biography was founded with a simple conviction: that the breakthroughs of the Biology Century deserve to reach humanity, faster.
Science today is advancing at unprecedented speed—rewriting what we know about disease, health, longevity, and possibility. But innovation alone is not enough. What matters is whether these ideas make it past the bottlenecks of development, gain understanding and trust, and reach the people who need them most.
Biography was born to stand alongside the leaders building this future. We believe this moment demands more than incremental progress—it demands conviction, creativity, and a new model for communications. The work ahead is too important to leave to slow, siloed, or outdated models. Let’s make sure its promise is realized.
This is the Biology Century.
Together, we’ll deliver on its promise.
A team built for the Biology Century—bringing together MDs, PhDs, PharmDs, MBAs, and more.
Our bench spans scientists, strategists, engineers, creative technologists, and healthcare professionals from leading global consulting firms, agencies, and life sciences organizations. We are united by a commitment to shaping outcomes where science meets strategy and story.
Team
Partners
We’ve built exclusive partnerships with expert firms and collaborators—spanning strategy, medical and data and analytics domains. These relationships extend our bench in purposeful ways, giving clients access to best-in-class expertise without the noise of broad vendor networks. Each affiliation is carefully chosen to align with our standards of clarity, rigor, and impact.
01
PharmaScroll
Data and Analytics
02
Caledonia Life Sciences
Strategy Consulting
03
PharmaSage
Market Research
04
Anfield Strategy
Medical Strategy
Briefs
The Rise of RNA Beyond Vaccines
mRNA is finding a second act in oncology and rare disease
Context: After pandemic-era hype, RNA platforms are regaining credibility through smaller, targeted indications. Moderna, BioNTech, and new entrants are advancing personalized cancer vaccines and protein-replacement therapeutics.
Interpretation: RNA’s advantage is speed — from sequence to candidate — but long-term differentiation will depend on delivery innovation and durability of expression.
Perspective: The next wave of RNA success will come from fit-for-purpose design, not scale. Expect renewed M&A activity as delivery IP consolidates.
The AI Regulatory Submission is Coming
Draft guidance sets a framework for trustworthy AI in drug review
Context: In January 2025, the FDA issued draft guidance detailing how AI models can support regulatory decision-making across the drug and biologics lifecycle.
Interpretation: The document introduces a seven-step, risk-based framework requiring sponsors to define context of use, assess model risk, and document credibility evidence.
Perspective: FDA oversight of AI is shifting from exploration to expectation—regulatory readiness now includes transparent, validated, and well-governed AI systems.
The New Obesity-Care Economy
As GLP-1 demand surges, policy and payers are catching up.
Context: Prescriptions keep outpacing supply, and policy is shifting: OPM now requires FEHB carriers to cover at least one GLP-1 for obesity across plan options, signaling broader reimbursement momentum.
Interpretation: SELECT showed ~20% MACE reduction with semaglutide in adults with overweight/obesity without diabetes, reframing treatment as cardiovascular risk reduction, not just weight loss.
Perspective: Expect 2026 to cement obesity care as chronic CV prevention: formularies will lean on outcomes evidence and real-world data to prioritize sustained access and adherence.
Renal Denervation Enters U.S. Hypertension Care
FDA approvals create an interventional option for resistant hypertension.
Context: The FDA has cleared two renal denervation systems—Recor’s ultrasound Paradise (PMA P220023) and Medtronic’s radiofrequency Symplicity Spyral—bringing RDN into U.S. practice.
Interpretation: With approved devices, specialists gain a catheter-based adjunct for patients uncontrolled on meds; commercialization and center onboarding are underway.
Perspective: Expect 2026 focus on patient selection, payer coverage, and outcomes registries as health systems operationalize RDN at scale.
CKD Therapy Broadens Beyond Diabetes
SGLT2s cut kidney risk in CKD with or without diabetes.
Context: DAPA-CKD and EMPA-KIDNEY showed SGLT2 inhibitors reduce CKD progression and CV death across patients with and without diabetes.
Interpretation: 2025 NEJM data indicate finerenone + empagliflozin lowers albuminuria more than either alone, supporting combination strategies.
Perspective: Expect 2026 guidelines to embed earlier, combo-based kidney protection—tightening nephrology–primary care coordination.
EU JCA Reshapes Launches
Oncology and ATMPs now face an EU-wide evidence review.
Context: The EU HTA Regulation became applicable January 12, 2025, introducing joint clinical assessments (JCA) for new oncology medicines and ATMPs—centralizing comparative evidence review across Member States.
Interpretation: With JCA starting post-validation of the EMA submission, sponsors must align endpoints, comparators, and evidence packages earlier to satisfy both regulators and HTA bodies in parallel.
Perspective: Expect 2026 launches to hinge on pan-EU consistency—programs that pre-wire JCA needs with EMA dossiers will move faster to access; fragmented evidence will face delays.